Dr Justin Loke BM BCh PhD MRCP FRCPath

Dr Justin Loke

Institute of Cancer and Genomic Sciences
AACR- CRUK Transatlantic Fellow

Contact details

Centre for Clinical Haematology
Queen Elizabeth Hospital
Mindelsohn Way
B15 2GW

Dr Justin Loke trained at University of Cambridge and Oxford Medical School and then completed postgraduate haematology training in Birmingham. His specialist interest is in Acute Myeloid Leukaemia (AML) and he completed a PhD at the University of Birmingham under the supervision of Professor Constanze Bonifer in the epigenetic deregulation of AML, for which he was awarded a number of prizes from the Royal Society of Medicine and the Royal College of Pathologists.

Dr Loke subsequently completed a post-CCT fellowship with CRUK Clinical Trials Unit, Birmingham, and was a Consultant Haematologist at the Queen Elizabeth Hospital, Birmingham where he was involved in the development of supportive care studies in AML (PACE) and in the running of IMPACT transplant studies. 

He is currently an AACR-CRUK Transatlantic Fellow based in the Dana Farber Cancer Institute, Boston, USA with Professor Ben Ebert.


  • Fellow of the Royal College of Pathologists 2018
  • PhD, University of Birmingham 2017
  • Member of the Royal College of Physicians 2011
  • BM BCh, University of Oxford 2008
  • Master of Arts, University of Cambridge 2005


Dr Loke previously worked on a systematic review and meta-analysis of Mylotarg (Anti-CD33 antibody conjugated to calicheamicin) in the treatment of AML (Loke et al, Annals of Hematology 2015), a collaboration with the University of Birmingham Cancer Research UK Clinical Trials Unit. This was presented at the plenary session of the British Society of Haematology meeting and is now part of the evidence base for the NCCN guidelines for the management of AML, 2019, which is used internationally for the management of this condition. 

Subsequently, Dr Loke worked on an analysis of outcomes of patients with FLT3-ITD AML across the West Midlands region in the UK (Loke et al, Leukaemia 2015). This data showed that in a subgroup of patients with a homozygous form of this mutation, their outcome is particularly poor. 

More recently, (Loke et al, Cell Reports, 2017 and Loke et al, Blood Advances, 2018) whilst working in the Professor Bonifer lab (Institute of Cancer and Genomic Sciences, University of Birmingham) as a Kay Kendall Leukaemia Fund Research Fellow, Dr Loke showed that gene regulatory networks unique to different forms of AML expressing either RUNX1-ETO or RUNX1-EVI1, could be identified using DNAse hypersensitivity site mapping, with transcription factor footprinting. They showed different sets of transcription factors interact with each other in each form of AML, which may explain the differences in the prognoses of the patients with the different forms of AML. They also identified transcription factor dependencies unique to each type of AML which could lead to personalized therapy.

Following completion of postgraduate haematology training, Dr Loke worked as a Consultant Haematologist at University Hospital Birmingham, as a stem cell transplant physician and specialising in myeloid malignancies. He worked with the TAP and IMPACT trial teams to develop PACE, investigating the epidemiology of infections in patients with AML, including COVID-19. He also played an active role in the management of IMPACT studies, AMADEUS and COSI.

Dr Loke was subsequently awarded an AACR CRUK Transatlantic Fellowship to be based at the Dana-Farber Cancer Institute, Boston, USA working in the group of Professor Ben Ebert.


  • Teaching programme for the West Midlands Haematology Registrars
  • Associate of Higher Education Academy


Clinical research to improve outcomes of patients with AML, including improving disease stratification supportive care strategies for patients with AML undergoing intensive treatment.

Other activities

  • NCRI AML Working Party Subgroup
  • NCRI AML Supportive Care Secretary
  • EBMT Acute Leukaemia Working Party
  • Certificate of Completion of Training- Haematology 2019

Culture and collections

Schools, institutes and departments

Services and facilities